Market Cap (In TWD)
184.48 Billion
Revenue (In TWD)
5.1 Billion
Net Income (In TWD)
-623.83 Million
Avg. Volume
3.87 Million
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 281.0-735.0
- PE
- -
- EPS
- -
- Beta Value
- 0.51
- ISIN
- TW0006446008
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Ko-Chung Lin Ph.D.
- Employee Count
- -
- Website
- https://www.pharmaessentia.com
- Ipo Date
- 2014-03-11
- Details
- PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
More Stocks
-
SROYFSailfish Royalty Corp.
SROYF
-
PUBLI
-
EUREKAIEureka Industries Limited
EUREKAI
-
SUBEXLTDSubex Limited
SUBEXLTD
-
RISHIROOPRishiroop Limited
RISHIROOP
-
1268
-
SLL
-
CHEF